vs
德康医疗（DXCM）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是德康医疗的1.0倍（$1.3B vs $1.3B），德康医疗同比增速更快（21.6% vs -5.8%），过去两年德康医疗的营收复合增速更高（12.0% vs -6.1%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
DXCM vs RHI — 直观对比
营收规模更大
RHI
是对方的1.0倍
$1.3B
营收增速更快
DXCM
高出27.4%
-5.8%
两年增速更快
DXCM
近两年复合增速
-6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.3B |
| 净利润 | $267.3M | — |
| 毛利率 | 62.9% | 37.6% |
| 营业利润率 | 25.6% | 1.7% |
| 净利率 | 21.2% | — |
| 营收同比 | 21.6% | -5.8% |
| 净利润同比 | 153.6% | — |
| 每股收益（稀释后） | $0.67 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMRHI
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $994.2M | $1.5B | ||
| Q2 24 | $1.0B | $1.5B |
净利润DXCMRHI
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | — | ||
| Q3 25 | $283.8M | $42.9M | ||
| Q2 25 | $179.8M | $41.0M | ||
| Q1 25 | $105.4M | $17.4M | ||
| Q4 24 | $151.7M | — | ||
| Q3 24 | $134.6M | $65.5M | ||
| Q2 24 | $143.5M | $68.2M |
毛利率DXCMRHI
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | 37.6% | ||
| Q3 25 | 60.5% | 37.2% | ||
| Q2 25 | 59.5% | 37.2% | ||
| Q1 25 | 56.9% | 36.9% | ||
| Q4 24 | 58.9% | 38.8% | ||
| Q3 24 | 59.7% | 39.0% | ||
| Q2 24 | 62.4% | 39.2% |
营业利润率DXCMRHI
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 1.7% | ||
| Q3 25 | 20.1% | 1.0% | ||
| Q2 25 | 18.4% | 0.1% | ||
| Q1 25 | 12.9% | 2.9% | ||
| Q4 24 | 17.0% | 4.7% | ||
| Q3 24 | 15.3% | 4.1% | ||
| Q2 24 | 15.7% | 5.1% |
净利率DXCMRHI
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | — | ||
| Q3 25 | 23.5% | 3.2% | ||
| Q2 25 | 15.5% | 3.0% | ||
| Q1 25 | 10.2% | 1.3% | ||
| Q4 24 | 13.6% | — | ||
| Q3 24 | 13.5% | 4.5% | ||
| Q2 24 | 14.3% | 4.6% |
每股收益（稀释后）DXCMRHI
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.32 | ||
| Q3 25 | $0.70 | $0.43 | ||
| Q2 25 | $0.45 | $0.41 | ||
| Q1 25 | $0.27 | $0.17 | ||
| Q4 24 | $0.37 | $0.53 | ||
| Q3 24 | $0.34 | $0.64 | ||
| Q2 24 | $0.35 | $0.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $1.3B |
| 总资产 | $6.3B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DXCMRHI
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $464.4M | ||
| Q3 25 | $1.8B | $365.3M | ||
| Q2 25 | $1.2B | $380.5M | ||
| Q1 25 | $904.9M | $342.5M | ||
| Q4 24 | $606.1M | $537.6M | ||
| Q3 24 | $621.2M | $570.5M | ||
| Q2 24 | $939.2M | $547.4M |
股东权益DXCMRHI
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $1.3B | ||
| Q3 25 | $2.7B | $1.3B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.3B | $1.3B | ||
| Q4 24 | $2.1B | $1.4B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $2.4B | $1.5B |
总资产DXCMRHI
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $2.9B | ||
| Q3 25 | $7.5B | $2.8B | ||
| Q2 25 | $7.3B | $2.8B | ||
| Q1 25 | $6.8B | $2.7B | ||
| Q4 24 | $6.5B | $2.9B | ||
| Q3 24 | $6.4B | $3.0B | ||
| Q2 24 | $6.8B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.5M |
| 自由现金流经营现金流 - 资本支出 | — | $170.8M |
| 自由现金流率自由现金流/营收 | — | 13.1% |
| 资本支出强度资本支出/营收 | — | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $266.8M |
8季度趋势，按日历期对齐
经营现金流DXCMRHI
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $182.5M | ||
| Q3 25 | $659.9M | $77.4M | ||
| Q2 25 | $303.0M | $119.4M | ||
| Q1 25 | $183.8M | $-59.3M | ||
| Q4 24 | $301.4M | $154.8M | ||
| Q3 24 | $199.5M | $129.6M | ||
| Q2 24 | $279.4M | $142.0M |
自由现金流DXCMRHI
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | $170.8M | ||
| Q3 25 | $579.4M | $63.6M | ||
| Q2 25 | $208.9M | $104.2M | ||
| Q1 25 | $96.8M | $-71.7M | ||
| Q4 24 | $176.8M | $140.5M | ||
| Q3 24 | $88.3M | $111.8M | ||
| Q2 24 | $213.3M | $129.6M |
自由现金流率DXCMRHI
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 13.1% | ||
| Q3 25 | 47.9% | 4.7% | ||
| Q2 25 | 18.1% | 7.6% | ||
| Q1 25 | 9.3% | -5.3% | ||
| Q4 24 | 15.9% | 10.2% | ||
| Q3 24 | 8.9% | 7.6% | ||
| Q2 24 | 21.2% | 8.8% |
资本支出强度DXCMRHI
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 0.9% | ||
| Q3 25 | 6.7% | 1.0% | ||
| Q2 25 | 8.1% | 1.1% | ||
| Q1 25 | 8.4% | 0.9% | ||
| Q4 24 | 11.2% | 1.0% | ||
| Q3 24 | 11.2% | 1.2% | ||
| Q2 24 | 6.6% | 0.8% |
现金转化率DXCMRHI
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 2.33× | 1.80× | ||
| Q2 25 | 1.69× | 2.91× | ||
| Q1 25 | 1.74× | -3.42× | ||
| Q4 24 | 1.99× | — | ||
| Q3 24 | 1.48× | 1.98× | ||
| Q2 24 | 1.95× | 2.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
